Shorters obviously had understood the DOGE impact far greater than I did. Chart says these are going to test sub 90p. However we are down 45% from recent intraday high of 168 so the fall has been pretty brutal. Perhaps over done. I crystalised a loss in my non Isa shares this morning as I can offset a large slice of the loss through CGT liabilities. I don't see any near term drivers of recovery. But WTFDIK! |
hard to see when price will stabilise....interesting to see how the shorters adapt to this update ... |
Sold out this morning for a chunky loss. Don't really see any reason to remain invested here. |
Well I have bought a decent slug.
I am still so miffed for missing the 2 160ish spikes, though realistically I would have bought back almost immediately 20p ish lower |
According to the main man at ONT, Roche kit nowhere near as good, it seems to rival old legacy kit of theirs. Hopefully he's correct. Though he's conscious of rivals and their need to possibly infringe patents, He's watching, well that's how I read it but I'm not that bright. GLA |
Roche starts 2026, so not so immediate as the DT issues. At least we seem to have been spared the Illumina treatment from China yesterday in response to the tariffs.
Patience it seems on the NIH clarifications. |
 In terms of unknowns, the political situation in the US has to be the largest. I estimated the total knock on effect on turnover could be up to 25%, as it's likely not just NIH that will be forced to make changes.
"Outlook FY25 guidance
...Revenue is expected to grow by 20 - 23% on a constant currency basis, reflecting continued strong demand across the business but taking into consideration recent updates and risks to US Federal funding, in particular with the National Institutes of Health ("NIH"), and a tightening of export control restrictions:
o Federal funding including the NIH: there remains material uncertainty and risk to US NIH funding levels (and other Federal agencies) to which management estimate a total Group exposure of between 10-15% of revenues. Given the situation is still evolving, management have prudently assumed a material reduction pending further clarity..."
=========================
Not much about Roche, except to say that it's not currently seen as a direct competitor. [We don't yet have pricing on Roche]
=========================
Legal action not mentioned? |
04 March 2025
Oxford Nanopore Technologies plc
Annual results for the year ended 31 December 2024
Guidance achieved on the back of strong and accelerating momentum in H2 24 across all regions; investments made in operational platform position the Group strongly for 2025
Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Group"), the company behind a new generation of molecular sensing technology based on nanopores, today announces its preliminary results for the year ended 31 December 2024.
Gordon Sanghera, Chief Executive Officer, commented:
"I am pleased to be reporting another year of strong, underlying constant currency revenue growth of 23%, in line with guidance. We are particularly encouraged by the increasing momentum delivered across all regions into the second half of 2024, with overall underlying revenue growth at constant currency accelerating to 34%. This, together with good cost control, drove an improvement in our EBITDA loss in H2 and we expect this trend to continue in 2025.
"We have continued to innovate at pace to meet customer needs in our target markets. We launched four new products in 2024, two of which - GridION Q and ElysION - are aimed at our regulated customer base to drive adoption in new Clinical, BioPharma and Applied Industrial markets. We also continued to demonstrate strong commercial execution, announcing several landmark contracts and new strategic collaborations during the year, as well as progressing existing collaborations. These included partnerships with the UK Government, UK Biobank and Precision Health Research Singapore that will advance genomics-driven healthcare innovation globally.
"While we expect the macroeconomic and geopolitical backdrop to remain uncertain, we enter 2025 with strong operational momentum and a growing opportunity pipeline. Our highly differentiated platform, commercial capabilities and robust balance sheet continue to position us well to capture the substantial market opportunity and deliver long-term sustainable above market growth and attractive returns for our shareholders." |
Shorters obviously not expecting much from the results tomorrow. New low for the year. |
for those not following closely, full year results tomorrow
the last trading update was only 13 jan, with everything on track, viewed positively, share price rose to over 150. I'm not making any predictions. |
Shorters closing? |
It's looking more and more likely this will end up in US hands for peanuts! |
Thank you TIO. You must be a very happy man... |
Indeed. I am a cash investor so can ride out these fluctuations. I never find the bottom or the top! If it stays subdued I will crystalise the loss before the end of the tax year and offset to reduce my CGT liability. It all depends on what they say next week really. |
I wonder where we will find a bottom here....near term... |
ONT's key USP vs Illumina is the fact ONT can provide long to ultra long reads & all of the associated benefits.
I.e. for plasmid sequencing, Google Gemini says;
"When sequencing a plasmid, long-read sequencing is preferred over short-read sequencing because it allows you to capture the entire plasmid sequence in a single read, providing a more complete picture of the plasmid structure, especially when dealing with repetitive regions, while short reads would require assembling many smaller fragments, potentially leading to errors in complex areas like repeats or insertion sites; however, short-read sequencing is often still used for its higher accuracy and lower cost, sometimes combined with long-read sequencing for a more comprehensive analysis."
However, as per the plasmidsaurus CEO, most potential users aren't aware of or don't trust new alternatives like nanopore sequencing, so aren't inclined to switch from ILMN. Therefore adding in an improved short read option like Roche have proposed potentially creates an additional barrier to switching?
Roche isn't going for the long read market at present, I guess the unknown is whether they will in the future or indeed their tech is capable of doing so. What the release has done is amped up negative sentiment in NGS companies, so inevitably ONT has been swept down.
I'm sure ONT will be quizzed on the implications on their full year results call next week, so that will provide helpful context. |
hxxps://www.globenewswire.com/news-release/2025/02/20/3029971/0/en/Roche-unveils-a-new-class-of-next-generation-sequencing-with-its-novel-sequencing-by-expansion-technology.html
Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, immune disorders and neurodegenerative conditions
Combined with an innovative, high throughput sensor module, SBX uses expanded synthetic molecules to determine the DNA sequence of a target molecule, creating an ultra-rapid, scalable and flexible technology
Reducing the time from sample to genome from days to hours, this novel approach could significantly speed up genomic research, as well as translational and clinical applications in the years to come
Q. if our USP vs. Illumina etc is speed/cost, how will this new approach challenge us given the Roche emphasis on speed too?
hxxps://www.tipranks.com/news/ratings/sell-rating-issued-for-illumina-amid-competitive-threats-from-roches-ngs-platform (analysts starting to pick up on this) nai etc |
Haven't read all the posts so someone may have mentioned this but I think Roche weakness may be in the complexity of their "sophisticated biochemical process" and development of a surrogate polymer. More steps added to a process the more points of potential failure. |
Expanded collaboration enables richer, more cost-effective biological insights from single cell workflows
Published on: 23 February 2025
Oxford Nanopore Technologies announced today its expanded collaboration with 10x Genomics, Inc. to enable seamless compatibility between their latest technologies, bringing more accurate, cost-effective and accessible insights to single-cell transcriptomics research.
The certified compatibility is between 10x Genomics’ latest Chromium Universal GEM-X 3’ and GEM-X 5’ single-cell chemistries — which enhance sensitivity while reducing cost per cell — and Oxford Nanopore’s high-accuracy V14 chemistry. This integration allows researchers to capture full-length isoforms and detect genetic variants at scale and with precision.
Oxford Nanopore has also released a major update to its EPI2ME single cell analysis workflow, enabling SNP calling across full-length transcripts. This enhancement simplifies the identification of disease-linked mutations, including those associated with cancer.
"One of the key applications of Oxford Nanopore sequencing from 10x Genomics libraries is the ability to detect SNPs that are missed by legacy sequencing technologies, because they fall outside the relatively small coverage region of short reads," said Chris Wright, Head of EPI2ME at Oxford Nanopore Technologies. "Our latest analysis update is designed to streamline SNP extraction from nanopore single cell sequence data.”
Advancing single-cell analysis
Single-cell analysis is transforming biomedical research, offering scientists a higher-resolution view of how genes are expressed in individual cells. The combined innovations from Oxford Nanopore and 10x Genomics bring:
● A more complete view of gene expression – by combining 10x Genomics’ single-cell profiling with Oxford Nanopore’s sequencing of any read length, researchers can accurately detect full-length RNA isoforms, capturing biological insights often missed with legacy technologies.
● Improved mutation detection – SNP calling in single-cell data makes it possible to identify genetic variants linked to diseases such as cancer.
● Simplified, cost-effective workflows – seamless compatibility means users of 10x Genomics’ platform can easily integrate Oxford Nanopore sequencing, including the ability to sequence long fragments into existing pipelines, reducing complexity and minimising time to discovery.
To support researchers using 10x Genomics’ Chromium Universal Gene Expression assays, both companies have collaborated to make datasets for two single-cell samples (Jurkat & 293T) available online.
This strengthened collaboration reinforces Oxford Nanopore’s leadership in a new era of full-length isoform sequencing in single-cell solutions. By providing real-time, high-resolution sequencing that integrates seamlessly with 10x Genomics’ high-throughput platforms, Oxford Nanopore continues to drive innovation in cancer research, neuroscience, immunology, and beyond. |
Shorters smashing it. I have put in £40k+ late this pm. It may fall more but I think they are oversold and with results a couple of weeks away there is reason to be optimistic. |
What justification for a 10% fall? |
Ellison has already gone through the 10% with the aggregate holding, so now has ultimate blocking rights in any takeover situation (as alluded to earlier).
Clearly as Saba have learned, once you get near 30%, it can box you in against short sellers. But plenty of popcorn to be consumed until we reach that point! |
2.75m traded already. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
